RecruitingNCT07399730

Ravulizumab Outcomes in Polish Patients With aHUS

A Non-interventional Study Evaluating Ravulizumab Treatment Outcomes in Polish Patients With Atypical Hemolytic Uremic Syndrome

Sponsor

AstraZeneca

Enrollment

80 participants

Start Date

Jun 24, 2026

Study Type

OBSERVATIONAL

Conditions

Atypical Hemolytic Uremic Syndrome

Summary

This multicenter, observational cohort study uses retrospective collection of past medical history and prospective follow-up to capture longitudinal data on the management and clinical outcomes of patients with atypical hemolytic uremic syndrome (aHUS) treated with ravulizumab as part of routine clinical practice under Poland's National Drug Program (NDP).

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Ravulizumab for people with atypical hemolytic uremic syndrome. The study is currently recruiting participants at 10 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGRavulizumab

Ultomiris

Locations(10)

Research Site

Gdansk, Poland

Research Site

Katowice, Poland

Research Site

Katowice, Poland

Research Site

Krakow, Poland

Research Site

Lodz, Poland

Research Site

Poznan, Poland

Research Site

Warsaw, Poland

Research Site

Warsaw, Poland

Research Site

Wroclaw, Poland

Research Site

Wroclaw, Poland

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07399730

Related Trials

Evaluate Long-term Safety, Tolerability and Efficacy of Iptacopan in Study Participants With aHUS

NCT057951409 locations

Efficacy and Safety of Switching From Anti-C5 Antibody Treatment to Iptacopan Treatment in Study Participants With Atypical Hemolytic Uremic Syndrome (aHUS)

NCT0593521531 locations

Post-Marketing Clinical Study of Ravulizumab in Participants With Clinical aHUS

NCT0730857412 locations

The Burden of Atypical Hemolytic Uremic Syndrome and The Clinical Characteristics of Patients in Egyptian Hospitals A Multicenter, Observational, Retrospective Cohort Study in Egypt

NCT072185368 locations

Developing a Pipeline to Employ RNA-Seq as a Complementary Diagnostic Tool in Rare Diseases

NCT059967311 location